News
9h
GlobalData on MSNMTPA’s Radicava shows long-term benefit in ALS trials
MTPA's oral therapy Radicava (edaravone) has shown decreased functional decline and improved survival in long-term ALS trials ...
Neurizon Therapeutics has reported positive topline results from an open-label extension (OLE) study of its lead candidate ...
Jodi O’Donnell-Ames founded Hope Loves Company to provide support, resources, and community to children affected by ALS.
Summary: A new study has uncovered why some motor neurons resist degeneration in ALS while others succumb. Researchers found ...
Yet another biotech is facing a delay from the FDA as the agency reels from intense staffing cuts. | Yet another biotech is ...
By analyzing millions of messenger RNA molecules (mRNA) during the course of ALS, researchers at Stockholm University, in ...
The ALS therapy ATH-1105 entered the brain and spinal cord at dose-proportional levels in healthy volunteers, and had a good ...
2d
HealthDay on MSNFDA approves ketamine product for surgical pain management
The U.S. Food and Drug Administration has approved the ketamine product, KETARx, for use in surgical pain management.
10h
TipRanks on MSNNeuroSense Reports Long-Term Safety of PrimeC in ALS Study
The latest update is out from Neurosense Therapeutics Ltd. ( ($NRSN) ). As of August 20, 2025, NeuroSense Therapeutics Ltd. reported that ...
In a recent study, scientists successfully decoded not only the words people tried to say but the words they merely imagined ...
SineuGene gets China NMPA & US FDA nods to initiate phase I/IIa trial of gene therapy, SNUG01 to treat amyotrophic lateral sclerosis: Beijing Monday, August 18, 2025, 18:00 Hrs [I ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results